

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Oct 2021 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Apalutamide	Erleada	Malignant disease and immunosuppression	Approved	
2	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
3	Bevacizumab	Mvasi	Malignant disease and immunosuppression	Approved	
4	Burosumab	Crysvita	Endocrine system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
5	Dacomitinib	Vizimpro	Malignant disease and immunosuppression	Approved	
6	Daratumumab	Darzalex	Malignant disease and immunosuppression	Approved	
7	Dupilumab	Dupixent	Respiratory system	Approved	
8	Eftrenonacog alfa	Alprolix	Cardiovascular system	Pending	Pending further information
9	Entrectinib	Rozlytrek	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
10	Fentanyl citrate	PecFent	Central nervous system	Rejected	Concern regarding safety profile
11	Galcanezumab	Emgality	Central nervous system	Approved	
12	Indacaterol / Mometasone furoate	Aectura Breezhaler	Respiratory system	Approved	
13	Infliximab	Remicade	Gastro-intestinal system	Pending	Pending further information
14	Insulin glargine	Toujeo	Endocrine system	Pending	Pending further information
15	Ixekizumab	Taltz	Musculoskeletal and joint disease	Rejected	Alternative(s) available in HADF with comparable benefits
16	Lanreotide	Somatuline Autogel	Malignant disease and immunosuppression	Approved	
17	Larotrectinib	Vitrakvi	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
18	Lutetium oxodotreotide	Lutathera	Radiopharmaceuticals	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
19	L-arginine hydrochloride L-lysine hydrochloride	LysaKare	Nutrition and blood	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
20	Nivolumab / Ipilimumab	Opdivo / Yervoy	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
21	Omalizumab	Xolair	Skin	Approved	
22	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	
23	Polatuzumab vedotin	Polivy	Malignant disease and immunosuppression	Approved	
24	Rituximab	MabThera	Skin	Approved	
25	Rituximab	Truxima	Malignant disease and immunosuppression	Approved	
26	Sucroferric oxyhydroxide	Velphoro	Nutrition and blood	Approved	
27	Tafamidis	Vyndamax	Cardiovascular system	Approved	
28	Thiotepa	Tepadina	Malignant disease and immunosuppression	Approved	
29	Ustekinumab	Stelara	Gastro-intestinal system	Approved	
30	Venetoclax	Venclexta	Malignant disease and immunosuppression	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.